The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
CD47
Don’t eat me signal
Immunotherapy
Metastatic SGC treatment
Mucoepidermoid carcinoma
Oral Cancer
Salivary gland cancer
Tumor microenvironment
Tumor-infiltrating lymphocytes
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Sep 2022
28 Sep 2022
Historique:
received:
20
05
2022
accepted:
19
09
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
epublish
Résumé
Salivary gland carcinomas (SGC) are extremely rare malignancies with only limited treatment options for the metastatic phase of the disease. Treatment with anti-CD47 antibodies could represent a potent therapy for SGCs by promoting the phagocytic clearance of tumor cells through various mechanisms. However, the efficacy of anti-CD47 therapy is largely dependent on the expression of CD47 within the tumor microenvironment (TME). In 43 patients with SGC, we were the first to investigate the CD47 expression in both tumor cells and tumor-infiltrating immune cells (TIIC) in the center and periphery of primary tumors. We also correlated the data with the clinicopathological variables of the patients and offered novel insights into the potential effectiveness of anti-CD47 therapy in SGCs. We observed that the CD47 The reason for a high expression of 'don't eat me' signals in TIICs in the tumor periphery is unclear. However, we hypothesize that in the tumor periphery, upregulation of CD47 in TIICs could be a mechanism to protect newly recruited leukocytes from macrophage-mediated phagocytosis, while also allowing the removal of old or exhausted leukocytes in the tumor center.
Sections du résumé
BACKGROUND
BACKGROUND
Salivary gland carcinomas (SGC) are extremely rare malignancies with only limited treatment options for the metastatic phase of the disease. Treatment with anti-CD47 antibodies could represent a potent therapy for SGCs by promoting the phagocytic clearance of tumor cells through various mechanisms. However, the efficacy of anti-CD47 therapy is largely dependent on the expression of CD47 within the tumor microenvironment (TME).
MATERIALS AND METHODS
METHODS
In 43 patients with SGC, we were the first to investigate the CD47 expression in both tumor cells and tumor-infiltrating immune cells (TIIC) in the center and periphery of primary tumors. We also correlated the data with the clinicopathological variables of the patients and offered novel insights into the potential effectiveness of anti-CD47 therapy in SGCs.
RESULTS
RESULTS
We observed that the CD47
CONCLUSION
CONCLUSIONS
The reason for a high expression of 'don't eat me' signals in TIICs in the tumor periphery is unclear. However, we hypothesize that in the tumor periphery, upregulation of CD47 in TIICs could be a mechanism to protect newly recruited leukocytes from macrophage-mediated phagocytosis, while also allowing the removal of old or exhausted leukocytes in the tumor center.
Identifiants
pubmed: 36171566
doi: 10.1186/s12885-022-10114-4
pii: 10.1186/s12885-022-10114-4
pmc: PMC9520840
doi:
Substances chimiques
CD47 Antigen
0
CD47 protein, human
0
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1021Informations de copyright
© 2022. The Author(s).
Références
Mol Cancer Ther. 2020 Mar;19(3):835-846
pubmed: 31879362
Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938
pubmed: 30231352
Cancer Manag Res. 2020 Feb 11;12:1047-1067
pubmed: 32104086
Curr Opin Immunol. 2012 Apr;24(2):225-32
pubmed: 22310103
Cancer Immunol Res. 2019 Sep;7(9):1547-1561
pubmed: 31362997
Biochem Biophys Res Commun. 2006 May 19;343(4):1197-200
pubmed: 16580635
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Sci Rep. 2020 Aug 18;10(1):13936
pubmed: 32811852
Blood Rev. 2018 Nov;32(6):480-489
pubmed: 29709247
Sci Transl Med. 2010 Dec 22;2(63):63ra94
pubmed: 21178137
Oncotarget. 2017 Jan 17;8(3):3946-3956
pubmed: 27992367
Biomedicines. 2021 Jan 20;9(2):
pubmed: 33498270
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Blood. 2015 Jan 15;125(3):542-52
pubmed: 25411427
PLoS One. 2015 Mar 16;10(3):e0121071
pubmed: 25774992
Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-9
pubmed: 26317305
Sci Rep. 2020 Oct 12;10(1):16988
pubmed: 33046752
Nat Rev Immunol. 2006 Jun;6(6):457-64
pubmed: 16691243
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61
pubmed: 22451919
Front Oncol. 2020 Oct 22;10:580141
pubmed: 33194707
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Cell. 2010 Sep 3;142(5):699-713
pubmed: 20813259
J Biochem. 2014 Jun;155(6):335-44
pubmed: 24627525
Cancer Res. 2014 Dec 1;74(23):6771-83
pubmed: 25297630
Front Oncol. 2019 May 07;9:343
pubmed: 31134150
ESMO Open. 2016 Aug 26;1(4):e000083
pubmed: 27843633
J Immunol Res. 2020 Sep 19;2020:9435030
pubmed: 33015199
Am J Surg. 1991 Oct;162(4):330-6
pubmed: 1659242
Oncoimmunology. 2018 Mar 13;7(4):e1397248
pubmed: 29632717
Tumour Biol. 2008;29(1):28-34
pubmed: 18497546
Front Oncol. 2021 Jan 05;10:615534
pubmed: 33469516
Int J Mol Sci. 2015 Feb 04;16(2):3391-404
pubmed: 25658794
Cancer. 2005 Jun 15;103(12):2544-50
pubmed: 15880750
J Clin Oncol. 2019 Jan 10;37(2):125-134
pubmed: 30452336
J Clin Invest. 2016 Jul 1;126(7):2610-20
pubmed: 27294525
Theranostics. 2020 Mar 15;10(10):4383-4394
pubmed: 32292502
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
Mol Biol (Mosk). 2017 Mar-Apr;51(2):251-261
pubmed: 28537232
Clin Transl Oncol. 2016 Nov;18(11):1051-1055
pubmed: 26830085
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Crit Rev Oncog. 2018;23(3-4):139-151
pubmed: 30311570
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8
pubmed: 23690610
Blood. 2005 Jul 15;106(2):658-67
pubmed: 15784731
Biomedicines. 2021 Apr 08;9(4):
pubmed: 33917866